GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Manhattan Scientifics Inc (OTCPK:MHTX) » Definitions » Altman Z2-Score

MHTX (Manhattan Scientifics) Altman Z2-Score : -3,521.07 (As of Apr. 05, 2025)


View and export this data going back to 1998. Start your Free Trial

What is Manhattan Scientifics Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Manhattan Scientifics has a Altman Z2-Score of -3,521.07, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Manhattan Scientifics's Altman Z2-Score or its related term are showing as below:

MHTX' s Altman Z2-Score Range Over the Past 10 Years
Min: -3521.07   Med: -64.13   Max: 0.99
Current: -3521.07

During the past 13 years, Manhattan Scientifics's highest Altman Z2-Score was 0.99. The lowest was -3521.07. And the median was -64.13.


Manhattan Scientifics Altman Z2-Score Historical Data

The historical data trend for Manhattan Scientifics's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Manhattan Scientifics Altman Z2-Score Chart

Manhattan Scientifics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -109.87 -24.70 -72.80 -253.01 -815.32

Manhattan Scientifics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -446.55 -594.46 -815.32 -2,851.81 -3,521.07

Competitive Comparison of Manhattan Scientifics's Altman Z2-Score

For the Medical Devices subindustry, Manhattan Scientifics's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Manhattan Scientifics's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Manhattan Scientifics's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Manhattan Scientifics's Altman Z2-Score falls into.


;
;

Manhattan Scientifics Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Manhattan Scientifics's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-32.0405+3.26*-985.8784+6.72*-14.2703+1.05*-0.9787
=-3,521.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Jun. 2024:
Total Assets was $0.07 Mil.
Total Current Assets was $0.05 Mil.
Total Current Liabilities was $2.42 Mil.
Retained Earnings was $-72.96 Mil.
Pre-Tax Income was -0.158 + -0.382 + -0.254 + -0.262 = $-1.06 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Liabilities was $3.47 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(0.045 - 2.416)/0.074
=-32.0405

X2=Retained Earnings/Total Assets
=-72.955/0.074
=-985.8784

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-1.056 - 0)/0.074
=-14.2703

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(-3.4 - 0)/3.474
=-0.9787

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Manhattan Scientifics has a Altman Z2-Score of -3,521.07 indicating it is in Distress Zones.


Manhattan Scientifics  (OTCPK:MHTX) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Manhattan Scientifics Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Manhattan Scientifics's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Manhattan Scientifics Business Description

Traded in Other Exchanges
N/A
Address
244 Fifth Avenue, Suite 2341, New York, NY, USA, 10001
Manhattan Scientifics Inc is a company operating as a technology incubator that seeks to acquire, develop and commercialize life-enhancing technologies in the areas of nano-technologies and nano-medicines. The company continues to identify emerging technologies through strategic alliances with scientific laboratories, educational institutions, and scientists and leaders in industry and government. Its current focus is on the development of nanomaterials through the acquisition of Metallicum.
Executives
Chris Theoharis director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Photios Frank Georgiou director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Emmanuel Tsoupanarias director, officer: Chief Executive Officer 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Leonard Friedman director 405 LEXINGTON AVENUE, 26TH FLOOR, NEW YORK NY 10174
Marvin Maslow director, 10 percent owner, officer: Chief Executive Office MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
David Teich director, officer: Treasurer MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022
Ralph Anderson director 641 FIFTH AVENUE SUITE 36F, NEW YORK NY 10022
Larry H Schatz director 152 W. 57TH STREET, 31ST FLOOR, NEW YORK NY 10019
Marty Steinberg 10 percent owner 1111 BRICKELL AVENUE SUITE 2500, MIAMI FL 33131
Scott Bach director, officer: Secretary MANHATTAN SCIENTIFICS INC, 541 FIFTH AVE STE 36F, NEW YORK NY 10022

Manhattan Scientifics Headlines

No Headlines